Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of Taiwanese or Korean ancestry living in Taiwan or South Korea, respectively~* Have a diagnosis of plaque-type psoriasis at least 6 months prior to first administration of study agent (patients with concurrent psoriatic arthritis may be enrolled)~* Have plaque-type psoriasis covering at least 10% of total body surface area at screening and at the time of first study agent administration~* PASI score of 12 or greater at the time of screening and at time of first study agent administration~* Candidate of phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment)~* Be able to adhere to the study visit schedule and other protocol requirements~* Capable of giving informed consent prior to any study related procedures.~Exclusion Criteria:~* Currently have a non-plaque form of psoriasis~* Have current drug-induced psoriasis~* Are pregnant or nursing or planning pregnancy (both men and women) while enrolled in the study~* Have used any investigational drug within the previous 4 weeks or 5 times the half life of the investigational agent, whichever is longer~* Have used any biologic within the previous 3 months or 5 times the half life of the biologic, whichever is longer~* Have been hospitalized in the past 3 years for asthma, ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or required more than one short-term course of oral corticosteroids for asthma within the previous year~* Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis prior to screening.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo - Controlled Period (CP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab 45 mg - CP (Type: EXPERIMENTAL): None
- Placebo to ustekinumab 45 mg - after CP (Type: EXPERIMENTAL): None
- Ustekinumab 45 mg - after CP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).